+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

The safety and efficacy of hydroxyurea in 2 to 5 year old children with sickle cell disease



The safety and efficacy of hydroxyurea in 2 to 5 year old children with sickle cell disease



Pediatric Research 45(4 Part 2): 147A




Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 035932422

Download citation: RISBibTeXText


Related references

Efficacy and safety of deferasirox compared with deferoxamine in sickle cell disease: two-year results including pharmacokinetics and concomitant hydroxyurea. American Journal of Hematology 88(12): 1068-1073, 2014

Safety and efficacy of hydroxyurea in children and adolescents with sickle/beta-thalassemia: two-year experience. Hippokratia 19(2): 172-175, 2015

Three-year follow-up of hydroxyurea treatment in severely ill children with sickle cell disease. The French Study Group on Sickle Cell Disease. Journal of Pediatric Hematology/Oncology 19(4): 313-318, 1997

Safety and hematologic efficacy of four years of hydroxyurea therapy for very young children with sickle cell anemia The HUSOFT Extension Study. Blood 98(11 Part 1): 489a, November 16, 2001

Hydroxyurea is safe and effective in 2 to 5 year old children with sickle cell disease. Blood 94(10 Suppl. 1 Part 1): 417a, Nov 15, 1999

Hydroxyurea for sickle cell disease: a systematic review for efficacy and toxicity in children. Pediatrics 122(6): 1332-1342, 2008

Safety of hydroxyurea in children with sickle cell anemia: results of the HUG-KIDS study, a phase I/II trial. Pediatric Hydroxyurea Group. Blood 94(5): 1550-1554, 1999

A two-year pilot trial of hydroxyurea in very young children with sickle cell disease. Blood 94(10 Suppl. 1 Part 1): 644a, Nov 15, 1999

Sustained long-term hematological efficacy of hydroxyurea for children with sickle cell disease. Pediatric Research 51(4 Part 2): 239A, 2002

Hydroxyurea for the treatment of sickle cell disease: efficacy, barriers, toxicity, and management in children. Pediatric Blood and Cancer 59(2): 365-371, 2012

Sustained long-term hematologic efficacy of hydroxyurea at maximum tolerated dose in children with sickle cell disease. Blood 103(6): 2039-2045, 2003

Hydroxyurea treatment in patients affected with sickle cell anemia: efficacy and safety. Transfusion Clinique et Biologique 15(1-2): 34-38, 2008

Assessment of Safety and Efficacy of Peripheral Blood Stem Cell (PBSC) Mobilization with G-CSF in Haploidentical Maternal Donors with Sickle Cell Trait Prior to Haploidentical Stem Cell Transplantation in Their Children with High-Risk Sickle Cell Disease. Biology of Blood and Marrow Transplantation 21(2): S114-S116, 2015

Safety of hydroxyurea in children with sickle cell anemia: Results of the HUG-KIDS study, a phase I/II trial. Blood 94(5): 1550-1554, Sept 1, 1999

A two-year pilot trial of hydroxyurea in very young children with sickle-cell anemia. Journal of Pediatrics 139(6): 790-796, 2001